Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Figg

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Tumori|June 10, 1998
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancerA Thibault, W D Figg, R C Bergan, et al.
Molecular Urology|November 4, 2000
Comparative study of the clinical efficacy of two dosing regimens of flutamideJ B Thrasher, J Deeths, C Bennett, et al.
Pharmacotherapy|November 1, 1993
Anaphylactoid reaction with suraminA Thibault, W D Figg, M R Cooper, et al.
Archives of Dermatology|May 1, 2001
Drug-induced lupus associated with COL-3: report of 3 casesJ V Ghate, M L Turner, M A Rudek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignanciesJ Gilbert, S D Baker, M K Bowling, et al.
Anti-Cancer Drugs|June 1, 1994
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrateW D Figg, R G Walls, M R Cooper, et al.
Journal of the National Medical Association|September 26, 1997
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancerR C Bergan, R G Walls, W D Figg, et al.
Human Gene Therapy|May 1, 1999
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanomaB J Park, C K Brown, Y Hu, et al.
Journal of Pharmacokinetics and Biopharmaceutics|September 15, 1999
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parametersK S Bauer, E C Kohn, R M Lush, et al.
Cancer|April 15, 1995
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancerW D Figg, A Thibault, M R Cooper, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Tumori|June 10, 1998
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancerA Thibault, W D Figg, R C Bergan, et al.
Molecular Urology|November 4, 2000
Comparative study of the clinical efficacy of two dosing regimens of flutamideJ B Thrasher, J Deeths, C Bennett, et al.
Pharmacotherapy|November 1, 1993
Anaphylactoid reaction with suraminA Thibault, W D Figg, M R Cooper, et al.
Archives of Dermatology|May 1, 2001
Drug-induced lupus associated with COL-3: report of 3 casesJ V Ghate, M L Turner, M A Rudek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignanciesJ Gilbert, S D Baker, M K Bowling, et al.
Anti-Cancer Drugs|June 1, 1994
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrateW D Figg, R G Walls, M R Cooper, et al.
Journal of the National Medical Association|September 26, 1997
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancerR C Bergan, R G Walls, W D Figg, et al.
Human Gene Therapy|May 1, 1999
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanomaB J Park, C K Brown, Y Hu, et al.
Journal of Pharmacokinetics and Biopharmaceutics|September 15, 1999
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parametersK S Bauer, E C Kohn, R M Lush, et al.
Cancer|April 15, 1995
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancerW D Figg, A Thibault, M R Cooper, et al.
Pageof 14